Last Update: Sep 29, 2026
Clinical Experience With Iptacopan in Adult Patients With Complement 3 Glomerulopathy (C3G): A Multicenter, Observational, Retrospective Study of Patients Treated Through an Early Access Program in Spain
ClinicalTrials.gov Identifier:
Novartis Reference Number:CLNP023B1ES01
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
Study Description
This study aims to characterize the patient profiles and the clinical experience of iptacopan treatment in adult patients with C3G treated through an early access program (EAP) in Spain.
Complement 3 Glomerulopathy
Recruiting
35
Sep 22, 2026
Dec 15, 2026
All
18 Years - 100 Years (Adult, Older Adult)
Eligibility Criteria
Inclusion criteria:
1. Adult patients (≥18 years).
2. Biopsy-confirmed C3G.
3. Patients who have received at least one dose of iptacopan through an EAP from October 2020 to June 2025.
Exclusion criteria:
1\. Patients treated with iptacopan through an EAP for indications other than C3G.
Novartis Investigative Site
Recruiting
Madrid,28041,Spain
Worldwide Contacts
If the location of your choosing does not feature any contact detail, please reach out using the information below.